E
Evofem Biosciences
Biotech & Life Sciences · San Diego, United States · Founded 2009 · IPO 2014
Evofem Inc., a biotechnology company, develops reproductive and contraceptive care products for women worldwide MoreLess
Evofem Biosciences is a pioneering company in the sexual and reproductive healthcare sector, focusing on innovative, hormone-free contraceptive solutions. The company primarily serves women in the United States who are seeking non-hormonal, localized methods of birth control. Evofem operates in the pharmaceutical and healthcare markets, leveraging its extensive industry experience to introduce groundbreaking products that align with the growing trend towards natural and organic solutions. The business model revolves around the development, marketing, and sale of its flagship product, Phexxi, a hormone-free contraceptive gel. Revenue is generated through product sales, partnerships, and potentially through licensing agreements. Evofem's leadership team brings over 85 years of combined experience in healthcare and pharmaceuticals, ensuring robust strategic direction and execution. The company aims to empower women by providing them with more natural and effective contraceptive options, thereby addressing a significant gap in the market.
Keywords: hormone-free, contraceptive, women's health, pharmaceutical, Phexxi, non-hormonal, reproductive healthcare, innovation, natural products, U.S. market.
Company overview
Evofem Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2009
- Headquarters
- San Diego, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 32.8
- Investment activity
- 1 companies · latest Jul 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Evofem Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $100M | $100M | Aditxt | ↗ |
| POST IPO DEBTDebt | Feb 2023 | $1.4M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | May 2022 | $27M | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLEOther financing | Oct 2020 | $25M | — | Adjuvant Capital | — |
| POST IPO EQUITYOther financing | Jun 2020 | $100M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2019 | PDL Biopharma | — | ||
| EARLY VCOther financing | Aug 2017 | Undisclosed | — | ||
| SERIES DOther financing | Apr 2016 | Woodford Investment Management | — | ||
| EARLY VCOther financing | Nov 2015 | Undisclosed | — | ||
| IPOOther financing | Nov 2014 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $20M | 0% | $491K | 2.4% |
| 2025 | $20M | +4.2% | $491K | 2.4% |
| 2024 | $19M | +6.3% | −$8.3M | -42.8% |
| 2023 | $18M | +8.2% | −$90M | -491.3% |
| 2022 | $17M | +104.2% | −$94M | -555.9% |
| 2021 | $8.2M | +1748.4% | −$133M | -1615% |
| 2020 | $446K | — | −$67M | -14990.1% |
Growth signals
Evofem Biosciences website traffic
Latest recorded traffic for Evofem Biosciences is 4K monthly website visits, up 33.3% over the last three months. Evofem Biosciences's team declined 27.8% over the past year.
Comparisons
Evofem Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Evofem Biosciences investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Evofem Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Evofem Biosciences's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Evofem Biosciences has talent and traffic
In the news
Latest news about Evofem Biosciences
Recent press, funding announcements, and product moves mentioning Evofem Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Evofem Biosciences
An AI-synthesized read of the highest-engagement posts about Evofem Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evofem Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.